Yen Yun 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Oct 29, 2024
Insider Transaction Report
Form 4
Yen Yun
Director
Transactions
- Award
Options to Purchase Common Stock
2024-09-30+5,786→ 5,786 totalExercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (5,786 underlying)
Holdings
- 5,263(indirect: By Sino-American Cancer FDD)
Warrants to Purchase Common Stock
Exercise: $57.00From: 2020-11-30Exp: 2025-11-30→ Common (5,263 underlying) - 833
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 5,000
Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying) - 3,333
Options to Purchase Common Stock
Exercise: $16.80From: 2018-08-04Exp: 2023-08-04→ Common (3,333 underlying) - 4,527
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,527 underlying)
Footnotes (1)
- [F1]Effective September 30, 2024, the reporting person was granted stock options to purchase an aggregate of 5,786 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.